Viewing nowNeurocaba-PGI Capsule 75mg (Pregabalin)
Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

MFDS item code 201108892 · Approved 2011.10.21 · Insurance code 647803580
Treatment of neuropathic pain and fibromyalgia; adjunctive therapy for partial seizures of epilepsy
This medicine is used for the treatment of peripheral and central neuropathic pain in adults. It is also prescribed as an adjunct for partial seizures in epilepsy patients with or without secondary generalized symptoms. Finally, it is effective in the treatment of fibromyalgia. It helps to alleviate symptoms of these conditions and improve quality of life.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, with or without food. Since this medicine is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function (see section ‘5. Patients with renal impairment’). 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 2) Central neuropathic pain Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered (see section ‘4. Discontinuation’). 2. Epilepsy Adults: This medicine may be started at a dose of 150 mg daily. Based on each patient's response and tolerability, the dose may be increased to 300 mg daily after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg daily. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg-450 mg daily. The starting dose is 75 mg twice daily (150 mg daily), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg daily). For patients who do not experience sufficient benefit at a dose of 300 mg daily, the dose may be increased within 1 week to 225 mg twice daily (450 mg daily). Clinical studies were also conducted at a dose of 600 mg daily, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg daily are not recommended. 4. Discontinuation Based on current clinical experience, if this medicine is discontinued, it should be withdrawn gradually over at least 1 week. 5. Patients with renal impairment After entering the systemic circulation, this medicine is primarily excreted by the kidneys unchanged. The clearance of this medicine is directly affected by creatinine clearance; therefore, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (ml/min)* This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily pregabalin dose should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosing based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalin a Dosage regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: 150, 600, BID or TID ≥30 -<60: 75, 300, BID or TID ≥15 -<30: 25-50, 150, QD or BID <15: 25, 75, QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified under dosage regimen. b: The supplemental dose is an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older adults (aged 65 years or older) Dose reduction may be necessary in older adults with impaired renal function.
Children under 12 years of age: Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 ~17 years: Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or behavior during treatment, consult a doctor immediately. Those with hypersensitivity to this drug should not take it, and diabetic patients may need to adjust the dosage of blood glucose control medications due to weight gain. If symptoms of angioedema occur, such as swelling of the face or neck due to allergic reactions, it should be stopped immediately. Elderly patients are at risk of falls due to dizziness or drowsiness, so special caution should be exercised at the beginning of treatment. Some patients may experience blurred vision or changes in vision, which may improve upon discontinuation of the medication. If this medication is suddenly discontinued, withdrawal symptoms such as insomnia, headache, anxiety, and depression may appear; therefore, it should be gradually tapered under a doctor's supervision. Due to the risk of drug abuse, those with a history of substance abuse or mental disorders should inform their doctor beforehand. Patients with impaired kidney function may require dosage adjustments. Patients with severe heart diseases should use this drug with caution, as concomitant use with opioid analgesics may enhance central nervous system depression. Those with respiratory or neurological conditions, or the elderly, may be at a higher risk of severe respiratory depression and may require dosage adjustments. In early pregnancy, there is a risk of fetal malformations, so use during pregnancy should be avoided, and women of childbearing age should use effective contraceptive methods. Breastfeeding women should discontinue nursing while taking this medication, as it can be passed into breast milk and affect the baby. When engaging in risky activities such as driving or operating machinery, caution should be taken due to the risk of accidents caused by dizziness and drowsiness. If severe rashes or blisters appear on the skin while taking this medication, it should be stopped immediately and a doctor consulted. In case of overdose, symptoms such as confusion, drowsiness, depression, and seizures may occur; treatment such as hemodialysis may be necessary.
Not everyone experiences these, and they can vary from person to person.
This medicine should be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained between 15 to 30 degrees Celsius.
A hard capsule with a brown upper part and white lower part filled with white to light yellow powder
Domestically available - 30 capsules/bottle, Domestically available - 100 capsules/bottle, for export - 30 capsules/box[((10 capsules/PTP)*3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Yuyoung Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.